Compare CELC & EPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELC | EPRT |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.6B |
| IPO Year | 2017 | 2018 |
| Metric | CELC | EPRT |
|---|---|---|
| Price | $88.82 | $30.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $112.56 | $36.79 |
| AVG Volume (30 Days) | ★ 1.6M | 1.5M |
| Earning Date | 05-13-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 3.98% |
| EPS Growth | N/A | ★ 11.30 |
| EPS | N/A | ★ 0.28 |
| Revenue | N/A | ★ $561,219,000.00 |
| Revenue This Year | N/A | $17.12 |
| Revenue Next Year | $720.19 | $16.27 |
| P/E Ratio | ★ N/A | $110.29 |
| Revenue Growth | N/A | ★ 24.82 |
| 52 Week Low | $11.54 | $28.95 |
| 52 Week High | $151.02 | $34.73 |
| Indicator | CELC | EPRT |
|---|---|---|
| Relative Strength Index (RSI) | 31.63 | 50.16 |
| Support Level | $83.77 | $29.27 |
| Resistance Level | $117.61 | $31.75 |
| Average True Range (ATR) | 7.68 | 0.58 |
| MACD | -3.25 | 0.06 |
| Stochastic Oscillator | 9.24 | 60.98 |
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.